News | November 07, 2022
Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Revenue is up 23% whereas Profit After Tax expands 29% for the company
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
The training center will focus on providing radiation oncologists, radiotherapy technologists, and medical physicists with the necessary skills
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
The #Heart2HeartChallengeIndia campaign is very simple – you have to climb 60 steps in a minute, make a video of it, share it on your social media, tag 5 people, inviting them to take this challenge to check their heart health
To set up 50 lifestyle modification centres across the UAE in the next 24 months
Subscribe To Our Newsletter & Stay Updated
